Compass Pathways Plc (CMPS)
NASDAQ:CMPS
Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$6.66
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.66
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $14.76
Previous CloseN/A
Volume477.34K
Average Volume (3M)4.00M
Market Cap
$1.59B
Enterprise Value$640.85M
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume3,347,997
30 Day Avg. Volume3,995,568
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$23.50Price Target Upside252.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Robust Phase III DatasetA large, blinded Phase III dataset (>1,000 patients and 26-week follow-up) materially de-risks regulatory review and supports claims of durability and tolerability. That persistent clinical evidence strengthens the product's long-term commercial credibility and payer negotiation posture post-approval.
Rolling NDA And Priority VoucherA rolling NDA plus a Commissioner's National Priority Voucher structurally shortens potential review time and reduces regulatory timeline variability. This durable regulatory advantage can materially accelerate launch planning and shorten the horizon to revenue if clinical data remain supportive.
Low Leverage And Extended RunwayLow debt and a management-affirmed runway into 2028 provide multi-year financing flexibility to complete filing and initial commercialization. This reduces short-term solvency pressure and allows investment in commercial buildout and REMS/site onboarding without immediate refinancing risk.
Bears Say
Persistent Negative Cash FlowSustained large negative operating and free cash flow implies ongoing cash burn and dependence on external financing. Over the medium term this increases dilution risk and constrains discretionary commercial investments unless revenue ramps materially after approval.
Pre‑revenue With Large Operating LossesBeing pre-revenue with persistently large operating losses means margins and profitability are theoretical until product commercialization. This structural loss profile requires sustained capital and elevates execution risk around achieving profitable scale once market access and reimbursement are secured.
Reimbursement And REMS UncertaintyCategory III CPT status, pending RUC valuation, REMS specifics and DEA sequencing create prolonged reimbursement and access uncertainty. These structural payer and operational unknowns can suppress uptake, complicate revenue forecasting and extend the time to realize the product's market potential.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $2.25 and its highest was $14.76 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $1.59B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 43 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of -$0.439 by $1.149.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.39.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $0.71 in its last earnings report, beating expectations of -$0.439. Following the earnings report the stock price went up 16.969%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (252.85% Upside)
$23.50 (252.85% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
147.62%
12-Months-Change
Fundamentals
Return on Equity
-151.02%
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$23.50
▲(252.85% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.41% Insiders
1.28% Mutual Funds
52.49% Other Institutional Investors
42.45% Public Companies and Individual Investors